Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring

Medical Science Monitor

Volumn 16, Issue 5, 2010, Pages

  Ast, Jaroslaw ^a   Jablecka, Anna ^a   Bogdanski, Pawel ^a   Smolarek, Iwona ^a   Krauss, Hanna ^a   Chmara, Ewa ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

ABPM; Hypertension; L arginine

Indexed keywords

ARGININE; PLACEBO; ANTIHYPERTENSIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; CASE CONTROL STUDY; HYPERTENSION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ANTIHYPERTENSIVE AGENTS; ARGININE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES;

EID: 77954296378     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Celermajer DS, Sorensen KE, Bull C et al: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coli Cardiol, 1994; 24: 1468-74
2. Feihl F, Liaudet L, Waeber B, Levy BI: Hypertension: a disease of the microcirculation? Hypertension, 2006; 48(6): 1012-17
3. Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640-42
4. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980; 288: 373-76
5. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987; 327: 524-26
6. Palmer RM, Rees DD, Ashton DS, Moncada S: L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun, 1988; 153: 1251-56
7. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med, 1993; 329: 2002-12
8. Kelm M: The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep, 2003; 5(1): 80-86
9. Chowdhary S, Nuttall SL, Coote JH, Townend JN: L-arginine augments cardiac vagal control in healthy human subjects. Hypertension, 2002; 39(1): 51-56
10. Preli RB, Klein KP, Herrington DM: Vascular effects of dietary-arginine supplementation. Atherosclerosis, 2002; 162(1): 1-15
11. Cable D, Celotto A, Evora P, Schaff H: Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit, 2009; 15(9): BR248-53
12. Wilcken D, Sim A, Wang J, Wang X: Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab, 2007; 91(4): 309-17
13. Wu G, Meininger CJ, Knabe DA et al: Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care, 2000; 3: 59-66
14. Siasos G, Tousoulis D, Antoniades C et al: L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int J Cardiol, 2007; 116: 300-8
15. Palloshi A, Fragasso G, Piatti P et al: Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol, 2004; 93: 933-35
16. Lekakis JP, Papathanassiou S, Papaioannou TG et al: Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol, 2002; 86: 317-23
17. Gokce N: L-Arginine and Hypertension. J Nutr, 2004; 134: 2807-11
18. Böger RH, Bode-Böger SM: The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol, 2001; 41: 79-99
19. Weber MA: Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens Suppl, 2006; 24: 37-44
20. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003; 21: 1011-53
21. O'Brien E, Asmar R, Beilin L et al: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens, 2003; 21: 821-48
22. O'Brien E, Asmar R, Beilin L et al: Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens, 2005; 23: 697-701
23. O'Brien E, Waeber B, Parati G et al: Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ, 2001; 322: 531-36
24. Hozawa A, Ohkubo T, Kikuya M et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res, 2002; 25: 57-63
25. Mimran A, Ribstein J, DuCailar G: Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension, 1995; 26: 937-41
26. Jay MT, Chirico S, Siow RC et al: Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Exp Physiol, 1997; 82: 349-60
27. Kikuta K, Sawamura T, Miwa S et al: High-Affinity Arginine Transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ Res, 1998; 83: 1088-96
28. Perticone F, Sciacqua A, Maio R et al: Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol, 2005; 46: 518-23
29. Schlaich MP, Parnell MM, Ahlers BA et al: Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation, 2004; 110: 3680-86
30. Loscalzo J: L-arginine and atherothrombosis. J Nutr, 2004; 134: 2798-800
31. Wang JG, Staessen JA, Franklin SS et al: Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension, 2005; 45: 907-13
32. Fahey T, Schroeder K, Ebrahim S: Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev, 2005(1): p. CD005182
33. Weber MA: Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens Suppl, 2006; 24: 37-44
34. Yusuf S, Sleight P, Pogue J et al: Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study Investigators. N Engl J Med, 2000; 342: 145-53
35. MacMahon S, Rodgers A: The effects of blood pressure reduction in older patients: an overview of five randomized control/ed trials in elderly hypertensives. Clin Exp Hypertens, 1993; 15: 967-78
36. MacMahon S, Rodgers A, Neal B, Chalmers J: Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension, 1997; 29: 537-38